PDF(Pubmed)
Abstract：
UNASSIGNED: Muscle cramps are witnessed in 22-88% of patients with cirrhosis of liver and frequently lead to sleep disturbance with an appalling impact on quality of life. Despite such a high prevalence, there is lack of evidence-based management protocol due to scarcity of trials on treatment options in the literature. This study aimed to review systematically the available therapeutic options for muscle cramps in patients with cirrhosis of liver.
UNASSIGNED: A systematic review of the relevant databases (PubMed, Scopus, Embase, and Web of Science) to identify treatments for muscle cramps in patients with hepatic cirrhosis was performed. Studies meeting the selection criteria were reviewed and assessed for risk of bias and analyzed.
UNASSIGNED: Twenty-four publications were identified as eligible for inclusion in this systematic review. Seven randomized controlled trials (RCTs) and 17 prospective studies were included. Taurine, methocarbamol, baclofen, and orphenadrine are relatively safer and effective treatment option for muscle cramps in cirrhosis on the basis of recently conducted RCTs. Moreover, l-carnitine, branched-chain amino acids (BCAAs), pregabalin, zinc, and vitamin D are also safe and showed beneficial effects on muscle cramps. However, studies on vitamin E revealed contradictory results.
UNASSIGNED: Taurine, BCAAs, orphenadrine, and baclofen are safe and well-tolerated treatment options for muscle cramps in cirrhosis. However, well-designed randomized controlled clinical trials are the need of the hour to determine the most suitable treatment options for skeletal muscle cramps in patients with cirrhosis of liver.
UNASSIGNED: A systematic review of the relevant databases (PubMed, Scopus, Embase, and Web of Science) to identify treatments for muscle cramps in patients with hepatic cirrhosis was performed. Studies meeting the selection criteria were reviewed and assessed for risk of bias and analyzed.
UNASSIGNED: Twenty-four publications were identified as eligible for inclusion in this systematic review. Seven randomized controlled trials (RCTs) and 17 prospective studies were included. Taurine, methocarbamol, baclofen, and orphenadrine are relatively safer and effective treatment option for muscle cramps in cirrhosis on the basis of recently conducted RCTs. Moreover, l-carnitine, branched-chain amino acids (BCAAs), pregabalin, zinc, and vitamin D are also safe and showed beneficial effects on muscle cramps. However, studies on vitamin E revealed contradictory results.
UNASSIGNED: Taurine, BCAAs, orphenadrine, and baclofen are safe and well-tolerated treatment options for muscle cramps in cirrhosis. However, well-designed randomized controlled clinical trials are the need of the hour to determine the most suitable treatment options for skeletal muscle cramps in patients with cirrhosis of liver.
摘要：
■在22-88％的肝硬化患者中观察到肌肉痉挛，并经常导致睡眠障碍，对生活质量产生令人震惊的影响。尽管流行率如此之高,由于文献中关于治疗方案的试验较少,因此缺乏循证管理方案.本研究旨在系统地回顾肝硬化患者肌肉痉挛的可用治疗选择。
■对相关数据库的系统评价(PubMed，Scopus,Embase,和WebofScience）以确定肝硬化患者肌肉痉挛的治疗方法。对符合选择标准的研究进行审查，并评估偏倚风险并进行分析。
■确定有24篇出版物有资格纳入本系统评价。纳入7项随机对照试验（RCT）和17项前瞻性研究。牛磺酸,美托卡莫,巴氯芬,根据最近进行的随机对照试验，奥芬纳丁是肝硬化肌肉痉挛相对安全有效的治疗选择。此外，左旋肉碱,支链氨基酸（BCAAs），普瑞巴林,锌，和维生素D也是安全的，对肌肉痉挛有有益的作用。然而,对维生素E的研究揭示了矛盾的结果。
■牛磺酸，BCAA,orphenadrine,巴氯芬是治疗肝硬化肌肉痉挛的安全且耐受性良好的治疗选择。然而,精心设计的随机对照临床试验需要一个小时来确定肝硬化患者骨骼肌痉挛的最合适的治疗方案。
■对相关数据库的系统评价(PubMed，Scopus,Embase,和WebofScience）以确定肝硬化患者肌肉痉挛的治疗方法。对符合选择标准的研究进行审查，并评估偏倚风险并进行分析。
■确定有24篇出版物有资格纳入本系统评价。纳入7项随机对照试验（RCT）和17项前瞻性研究。牛磺酸,美托卡莫,巴氯芬,根据最近进行的随机对照试验，奥芬纳丁是肝硬化肌肉痉挛相对安全有效的治疗选择。此外，左旋肉碱,支链氨基酸（BCAAs），普瑞巴林,锌，和维生素D也是安全的，对肌肉痉挛有有益的作用。然而,对维生素E的研究揭示了矛盾的结果。
■牛磺酸，BCAA,orphenadrine,巴氯芬是治疗肝硬化肌肉痉挛的安全且耐受性良好的治疗选择。然而,精心设计的随机对照临床试验需要一个小时来确定肝硬化患者骨骼肌痉挛的最合适的治疗方案。
